Eli Lilly's Market Leadership: Overall Obesity Dominance Intact, but Oral Foundayo Lags as Generic Tirzepatide Threat Looms

Eli Lilly's Market Leadership: Overall Obesity Dominance Intact, but Oral Foundayo Lags as Generic Tirzepatide Threat Looms

While Eli Lilly & Co. (NYSE: LLY) continues to command the lion's share of the broader U.S. anti-obesity market, the company is navigating a series of strategic headwinds in mid-2026. These include a sluggish launch for its oral GLP-1 weight-loss pill, Foundayo (orforglipron), and a historic regulatory milestone as generic competitors Sandoz and Hybio file the first Abbreviated New Drug Applications (ANDAs) to challenge Lilly's tirzepatide patents.

Dominant Overall Market Share Powered by Injectables

Despite challenges in the oral segment, Eli Lilly maintains a dominant 59.5% share of the overall U.S. obesity market as of July 2026. This market leadership is sustained by the massive popularity and dual-format distribution of its injectable tirzepatide (Zepbound):

• Zepbound Autoinjector: ~375,000 weekly prescriptions.
• Zepbound DTC Vial + KwikPen: ~289,000 weekly prescriptions.
• Combined, Lilly's weekly Zepbound prescriptions hover around 660,000, comfortably outstripping Novo Nordisk's total Wegovy scripts of roughly 448.5K.

Foundayo's "Muted" Launch Trajectory

Lilly's oral non-peptide GLP-1 receptor agonist, Foundayo (orforglipron), has experienced a slow start since its April 2026 commercial debut. Lilly has captured only about 11% of the new oral weight-loss pill market, with Novo Nordisk's oral Wegovy commanding the remaining 89%.

Key metrics and hurdles for Foundayo include:

• Script Tracking: For the week ending July 17, 2026, Foundayo logged 24,303 total prescriptions (representing a slight inflection from a flat five-week plateau of ~20,000 scripts). By comparison, Novo's oral Wegovy recorded 147,500 scripts in the same week.
• Efficacy Gap: Clinical trial data indicates that oral Wegovy achieved an average 16.6% body weight reduction after more than a year, compared to 12.4% for Foundayo.
• PBM Coverage Lag: CVS Caremark was the last of the big three pharmacy benefit managers (PBMs) to cover Foundayo, adding it on June 1, 2026. Oral Wegovy, by contrast, enjoyed comprehensive PBM coverage from its first week of launch.¹
• Brand Familiarity: Lilly executives note that establishing "Foundayo" as a new brand requires significant time and education, whereas Novo Nordisk benefits from the immediate, household-name recognition of its "Wegovy" brand.

Jefferies analysts have modeled $71 million in U.S. sales for Foundayo's debut quarter (April-June 2026), falling short of the Wall Street consensus of $130 million, though they still believe the drug can reach its full-year consensus estimate of $1.2 billion.

Generic Tirzepatide ANDA Submissions Threaten Long-Term Monopoly

In a major structural shift, the U.S. FDA accepted two Abbreviated New Drug Applications (ANDAs) from Swiss generics giant Sandoz on June 29, 2026 for proposed generic versions of tirzepatide autoinjectors. This was immediately followed on June 30, 2026 by the FDA's acceptance of similar generic tirzepatide applications from Chinese drugmaker Hybio Pharmaceutical.

• Scope: The generic applications cover all approved indications of Lilly's blockbusters Mounjaro (Type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).
• Patent Challenge: While Lilly's U.S. patents on tirzepatide are valid until 2036, these ANDA filings represent Paragraph IV patent challenges. This will trigger patent litigation from Lilly, initiating an automatic 30-month FDA approval stay while the parties litigate or negotiate a settlement date for generic market entry.
• Sandoz's President of Generics Development, Claire D’Abreu-Hayling, stated:

  "Sandoz is building its GLP-1 development platform and this submission reflects true in-house innovation. It represents a key first step in our efforts to bring this medicine to market and underscores our ambition to increase competition and expand affordability..."